Natera (NTRA) said Monday that it added a new feature to its Prospera Heart test to improve the detection of both acute cellular rejection and antibody-mediated rejection in heart transplant patients.
The company said the new Donor Quantity Score feature in Prospera Heart serves as a "second metric" that improves the accuracy of the test's risk assessment for antibody-mediated rejection and acute cellular rejection.
Shares of Natera were up 1.5% in recent trading.
Price: 111.84, Change: +1.64, Percent Change: +1.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments